Literature DB >> 16214090

CD20: a target antigen for immunotherapy of autoimmune diseases.

Federico Perosa1, Elvira Favoino, Maria Antonietta Caragnano, Marcella Prete, Franco Dammacco.   

Abstract

This article reviews the role of CD20 antigen in B cell function and the effectiveness and limits of passive immunotherapy with anti-CD20 monoclonal antibody (Rituximab) in the treatment of autoimmune (or immune-mediated) diseases. Active immunotherapy is a more feasible way to control these chronic diseases. A peptide that mimics the CD20 epitope recognized by Rituximab is employed to stimulate the host immune response against CD20.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16214090     DOI： 10.1016/j.autrev.2005.04.004

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN： 1568-9972            Impact factor:   9.754


  23 in total

Review 1.  Wegener's granulomatosis: is biologic therapy useful?

Authors:  Pasha Sarraf; Jonathan Kay; Robert P Friday; Anthony M Reginato
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

2.  An update on the management of chronic inflammatory demyelinating polyneuropathy.

Authors:  Kenneth C Gorson
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

3.  Functional recombinant extra membrane loop of human CD20, an alternative of the full length CD20 antigen.

Authors:  Mahdi Habibi Anbouhi; Aida Feiz Barazandeh; Saeid Bouzari; Mohsen Abolhassani; Hossein Khanahmad; Majid Golkar; Mohammad Reza Aghasadeghi; Mahdi Behdani; Ali Jahanian-Najafabadi; Mohammad Ali Shokrgozar
Journal:  Iran Biomed J       Date:  2012

4.  Prevention of Type 1 Diabetes Mellitus using a Novel Vaccine.

Authors:  Tihamer Orban; Janos Tibor Kis
Journal:  Ther Adv Endocrinol Metab       Date:  2011-02       Impact factor: 3.565

Review 5.  Regaining tolerance to a self-antigen by the modified vaccination technique.

Authors:  Arpad Zsigmond Barabas; Chad Douglas Cole; Rene Lafreniere; Donald Mackay Weir
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

6.  Multimodality imaging of coiled-coil mediated self-assembly in a "drug-free" therapeutic system.

Authors:  Rui Zhang; Jiyuan Yang; Te-Wei Chu; Jonathan M Hartley; Jindřich Kopeček
Journal:  Adv Healthc Mater       Date:  2015-01-21       Impact factor: 9.933

7.  Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events.

Authors:  Arpad Zsigmond Barabas; Chad Douglas Cole; Richard Milton Graeff; Rene Lafreniere; Donald Mackay Weir
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

8.  Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review.

Authors:  Anne Contis; Helene Vanquaethem; Marie-Elise Truchetet; Lionel Couzi; Claire Rigothier; Christophe Richez; Estibaliz Lazaro; Pierre Duffau
Journal:  Clin Rheumatol       Date:  2016-01-14       Impact factor: 2.980

9.  Outcomes of rituximab therapy in refractory lupus: A meta-analysis.

Authors:  Fatma Alshaiki; Elaf Obaid; Abdulqader Almuallim; Rabab Taha; Hadeel El-Haddad; Hani Almoallim
Journal:  Eur J Rheumatol       Date:  2018-02-13

Review 10.  Finding the root of the problem: the quest to identify melanoma stem cells.

Authors:  Ethan V Abel; Andrew E Aplin
Journal:  Front Biosci (Schol Ed)       Date:  2011-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.